Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c23b87fb72016f5f08590972ad5246c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7d318717c21d707eeb01bf8dd8963ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63260674da9e04b2f1f8f6f3e2549e28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75a6ddd792d227f009da6006b038f79e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-143333 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 |
filingDate |
2008-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0158d6b2b138f9fe60f25c7d9002b54b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e0a3f393ef26756fc48d65803c6a83a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1be62d436c6a12c5fd7a295dc0228d49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f05e54d62cfe1aba7e1b8eb961a90739 |
publicationDate |
2013-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8530621-B2 |
titleOfInvention |
Combined preparation of a thiazide diuretic and a loop diuretic |
abstract |
The specific molecular basis of the interaction between talin and integrin β 3 has been defined. This specific interaction provides a new therapeutic target; agents that can disrupt this specific interaction should be useful therapeutic agents for a number of significant diseases and conditions including inflammation, heart disease, including myocardial infarction, and tumor metastasis. The present invention includes a chimeric peptide that has high affinity for talin, muteins of talin and integrin β 3 as well as screening methods for agents that can disrupt the interaction between talin and integrin β 3 . |
priorityDate |
2007-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |